3SOF

Sonus Pharmaceuticals (SNUS) is focused on the development of novel drugs that may offer improved administration, tolerability, safety and effectiveness for the treatment of cancer and related conditions. The Company's lead product candidate is TOCOSOL(R) Paclitaxel, an injectable, ready-to-use formulation of the widely prescribed anti-cancer drug paclitaxel. TOCOSOL Paclitaxel has been designed to overcome the limitations associated with Taxol(R) and generic paclitaxel-based chemotherapy, including time consuming and expensive preparation of the products prior to administration, long infusion times and undesirable or treatment-limiting side effects.

The latest news on this company indicate that it enhanced a private placement of equity at prices not far below the current market price (Sonus Pharmaceuticals Raises $17.8 Million in Private Placement of Common Stock (http://www.marketwatch.com/tools/quotes/newsarticle.asp?dist=&param=archive&siteid=mktw&guid=%7BB14DF586%2D35CE%2D49A3%2D8FD5%2DB6AAA59E12C5%7D)), so institutions probably agree that this TOCOSOL drug has a good chance of getting to the final stage of being sold to the public.

Buy the rumor, sell the fact.

Technically we have one of the most reliable chart patterns, the double bottom, hence  my title on this recommendation:

(http://www.3stocksonfire.org/trading/index.php?action=dlattach;attach=4682;image)

We have a perfect double bottom and a bullish breakout today with volume above average. The technical target of this breakout is a modest $6.67, but the stock may run a lot further.

Let's take a look at the short term chart:

(http://www.3stocksonfire.org/trading/index.php?action=dlattach;attach=4683;image)

The risk is that this was a false breakout, but given the white marubozu with this kind of volume certainly it doesn't look like it is fake. You don't know it until you bet, with real money, like I'm going to do tomorrow when I buy SNUS for the 3 Stocks on Fire Portfolio, 6.66% of capital as usual.

(This recommendation was made by David Randolph from 3 Stocks on Fire, and he will update this analysis everyday after the close until he sells the stock. The 3 Stocks on Fire Portfolio is up 148% since inception on 28th of April 2005 (http://www.3stocksonfire.org/3stocksonfire.php). 3 Stocks on Fire is a Community of stock traders and investors. Our 3154 members exchange trading ideas and strategies on our message boards everyday. We welcome you as a new member of the 3 Stocks on Fire Community, please take 10 seconds to register (http://www.3stocksonfire.org/trading/index.php?action=register) and receive our free newsletter)

No love for SNUS?   Pretty dismal morning.  All i can find are talks of a buy out but no specifics what so ever.  Looks like we bought this one on a SPIKE.  Good thing HOM is doing its job and looking so pretty allowing me to sit on this.  What is your drop price at? 4.50?

the stock is still bullish under 4,50 as long as it closes above the ascending bullish trendline.

I will watch the pull back.. as long as it closes above the opening price of the white marubozu it is an interesting short term play... 

when I looked at the chart myself I got confused.. it looks quite different from yours (yours is linear?)

in the way I look at it it went up right to the ascending resistance of the bullish price channel:

more of my opinion here ;)
http://stock-diary.blogspot.com/2005/09/watchlist-snus.html

nikao, there is a channel of sorts and that is a good observation.....but two things David points out are even stronger in my opinion:

1) the strong and clear resistance at 4.5 (drawn as a horizontal resistance line versus the channels)

2) the massive volume that occurred on that day, more than any in almost 2 years

These two observations together indicate a strong technical event.  Of course we need to monitor the continued behavior.  Today it held and closed above the support (former resistance),and the pullback showed much less volume than the breakout -- which is good.  We will need to see what happens tomorrow, but hopefully good things are in store with the start of a new uptrend.  If we can't hold support though, dont waste time getting out.

I may look for a buy @ 4.35, but I'm wondering if we might see a handle on this cup formation (Mar-Aug). That would push my buy out a couple of weeks. What do you think?

After Hours (RT-ECN): 4.99  0.46 (10.15%)
IS anyone tracking this?  IS this a type-O?

AH is a typo as far as I know, Ameritrade streamer says $4.50 a share.

The question is:  How many shares?

Guys, from what I see after hours on SNUS was tiny 1700 shares at $4.53.

Sonus Pharmaceuticals to Present at Upcoming Investor Conferences

Thursday September 1, 6:30 pm ET


BOTHELL, Wash.--(BUSINESS WIRE)--Sept. 1, 2005--Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS - News) today announced that management will present at two investor conferences in September. These presentations will provide a company overview as well as a review of Sonus' strategic initiatives including the development of its lead oncology candidate, TOCOSOL® Paclitaxel, a novel paclitaxel product. At the end of June 2005, the Company completed a Special Protocol Assessment (SPA) with the FDA for the pivotal Phase 3 trial of TOCOSOL Paclitaxel. The Phase 3 trial will compare TOCOSOL Paclitaxel to Taxol® in the treatment of patients with metastatic breast cancer.
Sonus Conference Participation:

Roth Capital Partners New York Conference, September 7-8,
New York City
Sonus Presentation:  Thursday, September 8, 2:00 P.M. EDT/11:00 A.M.
PDT (live audio webcast and replay at www.sonuspharma.com/events.html)

ThinkEquity Partners Growth Conference, September 12-15, San Francisco
Sonus Presentation:  Thursday, September 15, 11:00 A.M. PDT/2:00 P.M.
EDT (live audio webcast and replay at www.sonuspharma.com/events.html)

About TOCOSOL Paclitaxel

TOCOSOL Paclitaxel is a ready-to-use, vitamin E-based emulsion formulation that allows a dose of paclitaxel to be infused over 15 minutes. In Phase 2 clinical trials, TOCOSOL Paclitaxel has generated encouraging data on safety and anti-tumor activity in multiple tumor types, including breast, ovarian, non-small cell lung and bladder cancers. Based on the promising clinical results to date, Sonus believes that TOCOSOL Paclitaxel may be shown to improve the treatment and therapeutic outcomes of patients treated with taxane products. The Company continues to advance TOCOSOL Paclitaxel towards Phase 3 testing to study the potential advantages of the product.

About Sonus Pharmaceuticals

Headquartered near Seattle, Washington, Sonus Pharmaceuticals, Inc. is focused on the development of therapeutic drugs that may offer improved administration, safety, tolerability and effectiveness for the treatment of cancer and related conditions. For additional information on the Company, including past news releases, please visit www.sonuspharma.com.

I still love SNUS and still think it is a sure play. We've had a pullback with very low volume to the breakout level of $4.5, just as it comes in the books.

Just a bit of wind and this can fly to new highs like a rocket. My cut off point would be the ascending trendline but I don't think we'll go down that far.

We've had some news but I don't have time to analyze them now (besides my trading plan is based on the chart, so the read would be for entertaining purposes only), I'll do that on the next update of SNUS.

I'm confortably holding the stock at this point.

Watch this close -- we have a possible "G" pattern forming here. :P

The long and short term charts have so many objective words in them that I'm afraid of spoiling the picture here. I don't know about you, but I have to buy a stock with this kind of double bottom pattern, in perfect harmony with the long term chart.

I'll continue holding SNUS, and since this is the last update before the open (from the 3 Stocks on Fire Portfolio, I will still update the 3 Pennies on Fire Portfolio), let me tell you that I'm very pleased with all my 9 holdings (Ramsburg has ANX too, which is doing allright).

Nothing new on SNUS, I'll continue holding the stock.

Hopefully we'll see some buying soon with this news:


Press Release Source: Sonus Pharmaceuticals, Inc.


Sonus Pharmaceuticals to Present at Upcoming Investor Conferences
Thursday September 1, 6:30 pm ET


BOTHELL, Wash.--(BUSINESS WIRE)--Sept. 1, 2005--Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS - News) today announced that management will present at two investor conferences in September. These presentations will provide a company overview as well as a review of Sonus' strategic initiatives including the development of its lead oncology candidate, TOCOSOL® Paclitaxel, a novel paclitaxel product. At the end of June 2005, the Company completed a Special Protocol Assessment (SPA) with the FDA for the pivotal Phase 3 trial of TOCOSOL Paclitaxel. The Phase 3 trial will compare TOCOSOL Paclitaxel to Taxol® in the treatment of patients with metastatic breast cancer.
Sonus Conference Participation:

Roth Capital Partners New York Conference, September 7-8,
New York City
Sonus Presentation:  Thursday, September 8, 2:00 P.M. EDT/11:00 A.M.
PDT (live audio webcast and replay at www.sonuspharma.com/events.html)

ThinkEquity Partners Growth Conference, September 12-15, San Francisco
Sonus Presentation:  Thursday, September 15, 11:00 A.M. PDT/2:00 P.M.
EDT (live audio webcast and replay at www.sonuspharma.com/events.html)

About TOCOSOL Paclitaxel

TOCOSOL Paclitaxel is a ready-to-use, vitamin E-based emulsion formulation that allows a dose of paclitaxel to be infused over 15 minutes. In Phase 2 clinical trials, TOCOSOL Paclitaxel has generated encouraging data on safety and anti-tumor activity in multiple tumor types, including breast, ovarian, non-small cell lung and bladder cancers. Based on the promising clinical results to date, Sonus believes that TOCOSOL Paclitaxel may be shown to improve the treatment and therapeutic outcomes of patients treated with taxane products. The Company continues to advance TOCOSOL Paclitaxel towards Phase 3 testing to study the potential advantages of the product.

About Sonus Pharmaceuticals

Headquartered near Seattle, Washington, Sonus Pharmaceuticals, Inc. is focused on the development of therapeutic drugs that may offer improved administration, safety, tolerability and effectiveness for the treatment of cancer and related conditions. For additional information on the Company, including past news releases, please visit www.sonuspharma.com.

Safe Harbor

Certain statements made in this press release are forward-looking such as those, among others, relating to the development, safety and efficacy of drug delivery products and potential applications for these products or the anticipated date of the initiation of the Phase 3 clinical trial for TOCOSOL Paclitaxel. As discussed in Sonus Pharmaceuticals' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K filed on March 23, 2005 and Form 10-Qs for the first two quarters of 2005, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: the Company's products will require extensive clinical testing and approval by regulatory authorities; such approvals are lengthy and expensive and may never occur; risks that the Company will not be able to initiate the Phase 3 clinical trial for TOCOSOL Paclitaxel; risks that clinical studies with TOCOSOL Paclitaxel will not be successful; risks that the FDA may not approve the Company's proposed New Drug Application; risks of successful development of additional drug delivery products; and risks that the Company may not be successful in obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies as well as research and development activities. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.


--------------------------------------------------------------------------------
Contact:
     Sonus Pharmaceuticals, Inc.
     Pamela L. Dull, 425-487-9500, Ext. 255



--------------------------------------------------------------------------------
Source: Sonus Pharmaceuticals, Inc.

You were right ultra1066, we've seen some buying on SNUS, but it failed to materialize into a meaningful rally. I have no problem with that, the stock seems to be on a consolidation phase and probably it will soon make its bullish move.

The reason for today's stock price dip is the registration with the SEC this morning of the 4,651,869 shares Sonus issued on August 15. See:

http://www.sec.gov/Archives/edgar/data/949858/000110465905042492/a05-15658_1s3.htm#SellingStockholders_005525

Effective today, Atlas Master Fund, Ltd. can sell 2,554,912 shares that they got for $3.77 per share. It behooves them to see it all as soon as they can to capture the arbitrage.

I have noticed that after private placement, some force will push the price up.

During the process the company normally will have some good news to support
their private placement.

Take SNUS for example, they announced $17.8 million placement on August 16 and positive news release August 18.

August 31 sees the biggest volume with price break out.

Ouch, that wasn't pretty  :P

It looks like SNUS chart was too good to be true. It was too easy. Now we have some doubt in the air. Yes, we've had a false breakout of the $4.5 resistance level, which was a very watched level, but the trend, defined by the ascending trendline, is still bullish.

The market is shaking the tree on SNUS. I'm still hanging and will continue to do so for as long as it closes above the ascending trendline which for today will stand at $4.07, rising $0.02 everyday.

We've had a 3.6% rise on SNUS but that wasn't great, because it still closed below $4.5 (or, at least, not above it).

I am a bit tempted to sell right away this losing position, because I'm short term bearish on the general market and the stock isn't strong enough to rise against a down market, but, I remember my past and what it cost me to get to this point in terms of discipline, and I know I will do better over time if I stick to my previously made trading plan.

So I will continue to hold SNUS for as long as it closes above the ascending trendline, which for today will be sitting at $4.08.

Quote from: David Randolph on September 12, 2005, 06:41:11 AM
Ouch, that wasn't pretty  :P

It looks like SNUS chart was too good to be true. It was too easy. Now we have some doubt in the air. Yes, we've had a false breakout of the $4.5 resistance level, which was a very watched level, but the trend, defined by the ascending trendline, is still bullish.

The market is shaking the tree on SNUS. I'm still hanging and will continue to do so for as long as it closes above the ascending trendline which for today will stand at $4.07, rising $0.02 everyday.


Don't want to be picky, but shouldn't that be $ 4,09 for today  ;)

You're right Amarens, it should be $4.09  :)

What happens is that sometimes these oblique lines differ a bit on Metastock, sometimes they occupy more than one value. Just a microscopic change in the slope may change values, so one shouldn't look for exact points, more for support and resistance zones or ranges.

For example, today I'm working on another computer, and on this the trendline for today stands at $4.14, instead of the expected $4.11. Many traders with many computers will see the trendline at slight different values, but in the same range.

Anyway, SNUS isn't behaving well and a drop to the ascending trendline is almost inevitable. But I don't find this action tradable, so what I'll do is to continue with my trading plan of holding for as long as the stock closes above the ascending trendline which for today is standing at $4.14.

SNUS=$4.375 > TL=$4.12 => HOLD SNUS

IF SNUS < $4.12 => SELL SNUS

(my computer went down, connectivity here is almost impossible, I'm unable to post annotated chart)

Stayed above trendline and it appears to have bounced off support around the 4.20-4.25 level.  Also staying inside big white candle of the end of August.

Thanks for the chart basonista, let me applaud you  :)

I said this two days ago:

QuoteAnyway, SNUS isn't behaving well and a drop to the ascending trendline is almost inevitable. But I don't find this action tradable, so what I'll do is to continue with my trading plan of holding for as long as the stock closes above the ascending trendline which for today is standing at $4.14.

So, the recent decline was expected. Though it wasn't tradable, at least not for position trading purposes, I don't want to waste time trading sardines here. That's to be done in the futures market, not with stocks, I believe.

Well, SNUS is coming down to the ascending trendline and it needs to bounce from that support line, or I'll have to sell. It's amazing how just a tiny correction to an ascending trendline can represent a 15% loss on these small priced stocks. Perhaps I should start looking to buy on declines to support instead of breakouts, those are proving to be the most profitable and fast profits.

For today I have the ascending trendline on SNUS at $4.18. I want to see a bounce from a touch on that level, if that fails to happen and the stock is set to close below $4.18 I'll take my loss and move on.

SNUS didn't touch support but bounced anyway. Volume was a bit stronger too (although still low on absolute terms, just 97,000 shares). Perhaps I'll need to redesign the trendline to reflect this behaviour from SNUS, the line was at $4.18 but the low on Friday was $4.25.

I'll leave it as it is for now, just want to check if this bounce will produce any material advance phase, I hope so. For tomorrow the ascending trendline will be at $4.19, I don't want to see SNUS closing below that level, or I'll sell.

The market needs to continue to agree that fundamentals are improving for me to keep holding the stock.

QuoteI'll leave it as it is for now, just want to check if this bounce will produce any material advance phase, I hope so. For tomorrow the ascending trendline will be at $4.19, I don't want to see SNUS closing below that level, or I'll sell.

I was a bit suspicious about Friday's advance on SNUS, the stock didn't touch support before the bounce. But now it did, it came down to touch support, so now it should bounce clearly to remain bullish. I believe this is what will indeed happen.

But I must respect the market will and wisdom, not mine. So if the stock breaks the ascending trendline on close, if it is set to close below $4.21 today, I have to sell and admit I was wrong on this trade.

I hope this stock keeps its uptrend going.Fundamentally speaking it is a good stock.How can the FDA not aproove its drug? It has a 67% better efficacy than its variant which is allready aprrooved.It seems like a no brainer to me.We'll just have to wait to see how long before they start stage 3 trials.I beleive they should have been started allready but we haven't seen any news.Thats when the stock really will climb higher.
jmo

Quote from: ultra1066 on September 20, 2005, 11:48:25 AM
I hope this stock keeps its uptrend going.Fundamentally speaking it is a good stock.How can the FDA not approve its drug? It has a 67% better efficacy than its variant which is allready approved.It seems like a no brainer to me.We'll just have to wait to see how long before they start stage 3 trials.I believe they should have been started allready but we haven't seen any news.Thats when the stock really will climb higher.
jmo

Thanks for your input ultra1066  :) I prefer not to enter into fundamental details when a stock is at a crucial technical point. I could fall in love with the fundamental story and then it would be harder to stick to the plan and practice an healthy discipline for long term above average performance.

Like every human being I have my weaknesses. As an investor I need to know those weaknesses and protect the trading capital from them. I believe this is very important, and it took me years to identify where I was weak and sorting out ways of dealing with those weaknesses.

For example, I trade the DAX futures for 7 years now. I had my streaks of wins (even bought a Porsche and a country house with the DAX profits  8)) and had some trading bankruptcies too (my futures trading account went to zero about 4 times in those 7 years  :-[).

I found out that it took me several months to have good gains and then I went down fast and lose it all in just a few days, to start all over again. Altough I was very good at trading for a long time suddenly I would break a sound money management rule and it was all lost, I was lost in the market and quickly all the profits and the initial capital went down the tube.

Why? I couldn't control myself. At some stage I would fall in love with a fundamental macro story or something and I would not only stick to a losing position, but I would even add to it. And then I was too big to fail, and of course I indeed failed. Everytime I raised my bets too much I went down big. This happened so many times that I knew I had to figure a way for this to never happen again. So I did the following:

I called my broker and told him to set my trading software to let me trade just one fixed amount of contracts. The system doesn't let me trade more than that number of contracts. I can only revise this every 2 months, with plenty of thought, not on an impulsive click.

I had more problems day trading the DAX futures and I dealt with them, not refusing that I had weaknesses, but embracing them and dealing with them, putting machines at my service.

Well, where was I? Which stock is this? Oh, let me talk about SNUS:

SNUS indeed reacted to the ascending support as we were thinking. Volume was very low though. I will hold the stock for as long as it closes above the ascending trendline, which for tomorrow will be standing at $4.24.

David,

Thank you for your input.It is wonderful to get direct feedback.That is the best way to learn and better ourselves.You would never get that with any other trading newsletter or website.
You are right, with stocks we tend to let our emotions (positive or negative) get in the way and affect the way we trade.

thank you so much for the insight and looking forward to continue getting your take on SNUS and the other stocks

Ultra

QuoteThank you for your input.It is wonderful to get direct feedback.That is the best way to learn and better ourselves.You would never get that with any other trading newsletter or website.

Thanks ultra1066  :D

I'll continue doing my best and I also have a lot to learn too. It amazes me how much there is to know about trading, yet, I want to inspire people and let them know that it is possible to achieve superior performance, it takes experience, knowledge and specially hard work like in any other business, but it's possible. Those that say it is impossible to beat the market probably never got to that stage, because it takes years of experience, study and sometimes financial pain to get there. If I can help making the path to success in trading shorter for at least some of 3 SOF Honours Members I will be a fortunate man.

SNUS volume is getting weaker and weaker, just about 50,000 shares traded today, that's nothing. But I will stick to the plan in the name of discipline, so I will hold the stock for as long as it closes above the ascending trendline which for tomorrow will be standing at $4.25.

Where did all the volume of the breakout at the 31st of August go?

SNUS is struggling with support here. Volume was too weak for a meaningful advance to unfold. It picked up somewhat today as the stock touched the ascending trendline again. Support for tomorrow stands at $4.26, if SNUS is set to close below the ascending trendline I'll take my loss and move on.

(Perhaps I should learn not to write such titles as «Cash in the pocket», I'll remind that lesson. The rest is normal trading risk)

I specifically said:

QuoteSupport for tomorrow stands at $4.26, if SNUS is set to close below the ascending trendline I'll take my loss and move on.

So all I could do was to take my loss, which I did, selling SNUS at $4.20. So much for «cash in the pocket». A good lesson for me as an analyst, to choose my titles more carefully. As trading goes this was normal trading activity and I have nothing to regret.

Hi David,

Not sure if you still look at a topic after closing the trade, therefore an email. You awaited the closing bell on SNUS, but still sold on the 23rd. I would like to know if this means you sold in the after hours?

Thanks in advance,
Amarens

I already answered you by e-mail Amarens, but let me answer here too: I sold on the regular market session when I saw that SNUS was set to close below $4.26, like I said I would.

I see that the stock closed down 4% on the after hours but that had nothing to do with me  ::)

I hope you don't own these shares anymore, if you do, good luck and be careful, an important support line was broken on the downside.

Here's the intraday and daily chart for SNUS:

(this thread will be removed to the Previous 3 SOF Picks Board (http://www.3stocksonfire.org/trading/index.php?board=15.0))

Why?

Was just surprised you sold during tradingday. Understood you never looked intraday.

Unfortunatly do own them and missed all the action on Friday, also would not have acted on intraday movement. That was a tip that gave me much more stability lately... Guess I learned now to set sell orders, when I'm not able to watch them  :-[ 

Anyway, I lesson learned!

Lets move on to the next!

Amarens

Glad I held on:

Sonus Pharmaceuticals Initiates Pivotal Phase 3 Trial of TOCOSOL(R) Paclitaxel for Treatment of Metastatic Breast Cancer
Wednesday September 28, 2:06 pm ET


BOTHELL, Wash.--(BUSINESS WIRE)--Sept. 28, 2005--Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS - News) today announced the initiation of the pivotal Phase 3 trial of TOCOSOL® Paclitaxel that is intended to serve as the basis for approval of the product by the U.S. Food and Drug Administration (FDA). The two-arm, randomized study is being conducted under a Special Protocol Assessment (SPA) that Sonus completed with the FDA in June 2005. The trial will enroll approximately 800 women with metastatic breast cancer, who will receive either TOCOSOL Paclitaxel or Taxol® on a weekly dosing schedule.
ADVERTISEMENT


The Phase 3 study's primary endpoint is objective response rate (ORR), and the New Drug Application (NDA) will be submitted based on analyses of data for that endpoint. Secondary endpoints of progression-free survival and overall survival are included in the trial design, and patient follow-up for those endpoints will continue following NDA submission. The Phase 3 trial will be conducted at approximately 150 clinical study sites in North America, Western and Eastern Europe, South Africa and Israel. The Company is anticipating that patient enrollment in the trial will be completed during the summer of 2006.

"Initiation of this Phase 3 trial is an important milestone towards achieving our goal of commercializing an innovative approach to taxane-based chemotherapy," said Michael A. Martino, president and chief executive officer. "We continue to be highly encouraged by the findings of our previous clinical studies, which suggest that TOCOSOL Paclitaxel may be an active anti-cancer agent that is well tolerated on a weekly basis. With the Phase 3 trial, we are optimistic that our novel TOCOSOL Paclitaxel product may be proven to be a better therapeutic alternative for women with metastatic breast cancer."

TOCOSOL Paclitaxel is a vitamin E-based emulsion formulation that allows a dose of paclitaxel to be infused over 15 minutes, and TOCOSOL Paclitaxel has been shown clinically to deliver substantially more active paclitaxel than can be achieved with Taxol. TOCOSOL Paclitaxel offers the convenience of a ready-to-use formulation that does not require preparation prior to administration, as required with marketed taxane products. Sonus has completed patient enrollment in Phase 2a studies of TOCOSOL Paclitaxel in non-small cell lung, ovarian and bladder cancers and has ongoing Phase 2b studies in breast and bladder cancers.

About Sonus Pharmaceuticals

Headquartered near Seattle, Washington, Sonus Pharmaceuticals, Inc. is focused on the development of therapeutic drugs that may offer improved administration, safety, tolerability and effectiveness for the treatment of cancer and related conditions. For additional information on Sonus, including past news releases, please visit www.sonuspharma.com.

------------------------

Up 7% as of this message

Keep SNUS on your watch list.


Ok, I'm gonna start pumping my "pharma stock". I keep finding
positive news. Things in the future are so postive for this company.
They are in phase III of their main product "TOCOSOL". It's an
improvement of an already existing anti cancer drug called
PACLITAXEL.



(Yearly sales of Paclitaxel are in excess of $1 billion.And they are
estimated to grow 20% yoy for 10 yrs.Here's an excerpt from an
article:


"Paclitaxel and related compounds (taxanes) are being evaluated in
new cancer drugs, in cardiovascular stents, and for other health
indications that should expand the market for Paclitaxel
considerably. Paclitaxel annual sales are in excess of one billion
dollars. It is estimated that the demand for Paclitaxel and related
compounds could grow by 20 percent annually over the next 10 years."

this quote found here if you want to read it:

http://www.paxispharma.com/paxisnews.htm



Since they have a product that they, lets say "add" to existing drugs
to improove efficacy, the possibilities of adding their technology to
other drugs to make them better, is endless. They could essentially
add their technology to all anticancer drugs that are injected to
increase their efficacy.

The key to a drug company in this stage is to have money for the
trials. They have no problem there because they recently signed an
agreement with SCHERING to finance the remainder of the study.

http://yahoo.businessweek.com/magazine/content/05_51/b3964083.htm



If your concerned about earnings Pharma stocks in these phases don't
need to post earnings just look at AMLN:

http://finance.yahoo.com/q?s=amln


Keep SNUS on your watch list for 06'

I own it and will patiently continue to.

Sonus Pharmaceuticals Keeps looking better as they close in on
completing enrollment for phase III for their anti cancer drug Tocosol
Paclitaxel. They have a heavyweight behind them in Schering who signed
a  licensing agreement with SNUS which payed $20 million up front and
includes $132 million more, so money won't be an issue while the
complete the studies. These moneys givem to SNUS is before sales when
they will split profits ( I forget the exact split). Also, this is not
a one drug company as they already are enrolling to start another
study on yet another anti cancer drug. They have a very unique aproach
to the drugs that they are trying to get approved. I'll try to explain
it: They take an allready existing chemo drug and improove it by
adding a "coat" of vitamin to it that helps to administer the drug
faster and easier and also helps stabilize and solubilize it improving
its eficacy, hopefully. I have been long SNUS since October or
November of last year ( i think) and This year and next will be very
good years for SNUS as they move closer to completing phase III, jmo
of course